Benjamin Mou

Benjamin Mou

British Columbia Cancer Agency - Vancouver / Canada
Medical and Health Sciences / Radiation Oncology
AD Scientific Index ID: 5387165
person_outline Benjamin Mou's MOST POPULAR ARTICLES
1-) Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trialR Olson, L Mathews, M Liu, D Schellenberg, B Mou, T Berrang, S Harrow, ...BMC cancer 20, 1-12, 2020912020
2-) Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical …R Olson, W Jiang, M Liu, A Bergman, D Schellenberg, B Mou, ...JAMA oncology 8 (11), 1644-1650, 2022322022
3-) Long-term clinical outcomes and safety profile of SBRT for centrally located NSCLCALH Arnett, B Mou, D Owen, SS Park, K Nelson, CL Hallemeier, T Sio, ...Advances in Radiation Oncology 4 (2), 422-428, 2019282019
4-) Progression-free survival and local control after SABR for up to 5 oligometastases: an analysis from the population-based phase 2 SABR-5 trialS Baker, W Jiang, B Mou, CR Lund, M Liu, AM Bergman, D Schellenberg, ...International Journal of Radiation Oncology* Biology* Physics 114 (4), 617-626, 2022282022
5-) Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5R Olson, M Liu, A Bergman, S Lam, F Hsu, B Mou, T Berrang, A Mestrovic, ...BMC cancer 18, 1-8, 2018232018